Amgen deploys patients to defend troubled Tavneos in FDA hearing request

Amgen is requesting an FDA hearing to defend Tavneos against a withdrawal recommendation, citing real-world evidence of benefit despite liver toxicity concerns that triggered safety alerts in the US, Japan, and Europe. The rare kidney disease drug faces mounting regulatory pressure globally after deaths and liver injuries emerged post-approval.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.